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Endocannabinoid peptides, or “pepcans,” are endogenous ligands of the CB1
cannabinoid receptor. Depending on their length, they display diverse activity: For
instance, the nona-peptide Pepcan-9, also known as hemopressin, is a powerful
inhibitor of CB1, whereas the longer variant Pepcan-12, which extends by only
three amino acid residues at the N-terminus, acts on both CB1 and CB2 as an
allosteric modulator, although with diverse effects. Despite active research on their
pharmacological applications, very little is known about structure-activity relationships
of pepcans. Different structures have been proposed for the nona-peptide, which has
also been reported to form fibrillar aggregates. This might have affected the outcome
and reproducibility of bioactivity studies. In an attempt of elucidating the determinants
of both biological activity and aggregation propensity of Pepcan-9 and Pepcan-12,
we have performed their structure characterization in solvent systems characterized by
different polarity and pH. We have found that, while disordered in aqueous environment,
both peptides display helical structure in less polar environment, mimicking the proteic
receptor milieu. In the case of Pepcan-9, this structure is fully consistent with the
observed modulation of the CB1. For Pepcan-12, whose allosteric binding site is still
unknown, the presented structure is compatible with the binding at one of the previously
proposed allosteric sites on CB1. These findings open the way to structure-driven design
of selective peptide modulators of CB1.
Keywords: pepcans, CB1 endocannabinoid receptor, endocannabinoid system, hemopressin, structure-activity
relationships, intrinsically unfolded peptides
INTRODUCTION
The name “pepcans” (endocannabinoid peptides) refers to a family of hemoglobin-derived
peptides that act as endogenous ligands of the cannabinoid (CB) receptor CB1 (Bauer et al.,
2012; Macedonio et al., 2016). This G-protein coupled receptor (GPCR) is widely expressed in
the nervous system and, together with the CB2 receptor, mostly expressed by immune cells,
is the primary target of endocannabinoids, such as anandamide and 2-arachidonoylglylcerol
(2-AG), and of phytocannabinoids, among which19-tetrahydrocannabinol (THC), themain active
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component of marijuana (Mechoulam and Parker, 2013;
Macedonio et al., 2016). The ensemble of endocannabinoids and
their receptors constitutes the Endocannabinoid System (ECS),
which is involved in a wide range of physiological processes
and manifestations, including cognitive function, pain, anxiety
and appetite regulation (Pagotto et al., 2006; Watkins and Kim,
2015; Reddy and Golub, 2016; Leone et al., 2017). A great wealth
of evidence has also linked the ECS to neuroprotection and
symptom reduction in models of many neurological diseases,
including multiple sclerosis, Alzheimer’s and Parkinson’s (van
der Stelt and Di Marzo, 2005; van der Stelt et al., 2006; Price
et al., 2009; Chiurchiù et al., 2018). Thus, modulation of CB1
and CB2 response by means of selective compounds poses
a stimulating challenge for drug design, also in light of the
observed psychoactive effects of the first generation of synthetic
cannabinoid drugs, which have led to their withdrawal from the
market (Cridge and Rosengren, 2013).
Typically, both endogenous and synthetic CB ligands are small
lipophilic molecules, with little common structural features.
Pepcans were discovered only 15 years ago (Rioli et al., 2003)
and their CB1 modulating activity was detected even more
recently (Heimann et al., 2007). Being the first reported peptide
modulators of the cannabinoid receptor, they have sparked
much interest, opening the possibility to develop peptide-
based scaffolds for pharmaceutical applications (Bomar and
Galande, 2013; Macedonio et al., 2016). Pepcan-9, also known as
hemopressin, was the first member of the family to be identified
in rat brain homogenates. It is a nona-peptide with amino acid
sequence PVNFKFLSH, corresponding to amino-acids 96–104
of the α-chain of hemoglobin (Heimann et al., 2007; Gomes
et al., 2010). Pepcan-9 was found to be a selective inverse agonist
of CB1, with an activity and a binding efficiency comparable
to that of the synthetic CB1 inhibitor rimonabant (Heimann
et al., 2007). The human homolog differs from the murine
peptide only by a Phe/Leu mutation at position 6, and has
similar activity (Bauer et al., 2012). Pepcan-9 administration
elicits a marked antinociceptive response (Heimann et al., 2007;
Toniolo et al., 2014) and produces hypotensive effects and
reduction of the food intake in animal models (Blais et al., 2005;
Dodd et al., 2010). Besides Pepcan-9, other N-terminal extended
hemopressin peptides have been isolated, referred to as Pepcan-
11 to Pepcan-23, according to their length (Bauer et al., 2012).
Indeed, experimental evidences suggest that, despite the observed
bioactivity, Pepcan-9 does not exist as such in vivo, being rather a
purification artifact of longer homologs, generated upon cleavage
of an extremely labile Asp-Pro peptide bond upon hot acid
extraction (Marcus, 1985; Gomes et al., 2010; Bauer et al., 2012;
Bomar and Galande, 2013). Independently from its existence
in vivo, the marked bioactivity, coupled to the possibility of
obtaining it with synthetic approaches, makes it interesting in
the perspective of potential pharmacological uses. Among the
longer peptide variants, the most abundant and active is Pepcan-
12 (RVD-hemopressin), which is expressed and released in the
central nervous system by noradrenergic neurons (Hofer et al.,
2015). Initial studies suggested that this peptide exhibited agonist
activity toward CB1 (Gomes et al., 2009), but later evidences
supported instead the view of Pepcan-12 as a negative allosteric
modulator (NAM) of CB1 (Bauer et al., 2012; Straiker et al.,
2015). A recent study by Petrucci et al. has demonstrated that the
peptide is also constitutively secreted in adrenals and liver upon
tissue damage and acts as a positive allosteric modulator (PAM)
of CB2 as well (Petrucci et al., 2017). Pepcan-12 is one of the
few known endogenous allosteric modulators of the CB receptors
(Morales et al., 2016). As allosteric modulation might be a
mean to fine tune, or even overcome, the adverse psychoactive
effects of some cannabinoid drugs, the understanding of the
molecular mechanisms of the phenomenon constitute a hot topic
in pharmaceutical research (Khurana et al., 2017). The allosteric
binding site for Pepcan-12 is still unknown, whereas, since
the introduction of chemical modifications at the N-terminus
greatly reduced its affinity toward CB1, this latter portion is
likely responsible for receptor binding (Bauer et al., 2012).
Exogenous administration of Pepcan-12 induces anorexigenic
and antinociceptive effects in rat models, with little or no side
effects (Han et al., 2014; Ferrante et al., 2017), and has been able
to restore impaired memory functions in Aβ1−42 treated mice,
highlighting its pharmacological versatility also in the treatment
of Alzheimer Disease-induced memory deficits (Zhang et al.,
2016). Given the proven involvement of the ECS in several
neurodegenerative diseases, the full pharmacological potential of
pepcans may yet to be fully revealed.
Despite all these promising findings, work with pepcans in
drug development has been hampered by the low reproducibility
of the pharmacological assays (Gomes et al., 2009), which
has been partially attributed to a certain propensity to
self-aggregation: for instance, under physiological conditions,
Pepcan-9 forms amyloid-like nanostructured fibrils, which may
precipitate from the solution, leading to inconsistent activity
reports (Bomar et al., 2012). Fibrillation has never been observed
for Pepcan-12 in similar conditions, despite the fact that these
pepcans differ only by the RVD extension at the amine terminus.
Additionally, little is known about the conformational properties
of pepcans in solution. Previous NMR studies on Pepcan-9
and its bioactive derivative, the C-terminally truncated hexa-
peptide (PVNFKF), employed DPC/SDS micelles to reproduce
the lipophilic receptor environment (Scrima et al., 2010). These
conditions induced the formation of regular β-turn structures
in the peptides, and docking studies on a homology model
of CB1 suggested that such conformations could explain the
binding to the same pocket as rimonabant (Scrima et al.,
2010). Very recently, the structure of the CB1 receptor has
been resolved by X-ray crystallography, in complex with both
agonist and antagonist compounds (Hua et al., 2016, 2017; Shao
et al., 2016). These structures have revealed that the receptor
is endowed with intrinsic plasticity and undergoes sensible
conformational changes correlating with its activation. Several
hydrophobic interactions with orthosteric ligands were detected,
differing from those proposed on the basis of the homology
model. In the present study, we describe the thorough structural
characterization of Pepcan-9 and Pepcan-12 with a dual intent:
to understand and overcome the aggregation propensity of
the peptides, we explored their conformational behavior both
in water and the presence of an apolar fluorinated alcohol,
hexafluoroisopropanol (HFIP), as a mean to mimic the low
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polarity of the receptor milieu. Both acidic and neutral pH
were employed, to understand whether the protonation state
of the peptide could drive the aggregation process. Finally, we
used docking studies to understand the possible binding modes
leading to differential CB1 activity modulation.
MATERIALS AND METHODS
Materials
Pepcan-9 and Pepcan-12 were synthesized by solid phase peptide
synthesis as previously reported (Remelli et al., 2016). HFIP,
both protonated and deuterated, and phosphate buffers were
purchased at the highest available purity from Sigma-Aldrich (St.
Louis, Missouri, USA) and used without further purification.
CD Spectroscopy
Stock solutions of Pepcan-9 and Pepcan-12 were prepared at
2mM concentration in 10mM HCl. Peptides solutions were
diluted in 20mM sodium phosphate buffer (NaP) at pH 3.0
or 7.4 to the final concentration of 20µM. CD spectra were
recorded on a Jasco J-715 spectropolarimeter (Jasco international
Co. Ltd, Tokyo, Japan) using a 0.1 cm path length quartz cuvette
at 20◦C in continuous scanning mode (20 nm/min, with a 4.0 s
response and a 1.0 nm band width). Three acquisitions were
averaged and the solvent contribution was subtracted for each
spectrum. The results are expressed as molar ellipticity [θ] (deg
cm2/mol). Deconvolution analyses were performed with the
BestSel software (Micsonai et al., 2015).
NMR Spectroscopy and Structure
Calculation
Stock peptide solutions were diluted to a final concentration of
500µM in 20mMNaP or in 50% v/v HFIP/NaP, at pH 3.0 or 7.4,
containing 5% D2O. 1D and 2D NMR experiments were carried
out at 298K on a 900 MHz Bruker AVANCE III instrument
equipped with a cryogenic probe. TOCSY experiments used a
mixing time of 80ms, NOESY spectra were acquired with 200
and 300ms mixing time, and ROESY spectra used a 100ms
spinlock. 2D spectra of 2048 × 512 complex points (12 × 12
ppm) were recorded with 32 scans. DQF-COSY was recorded
with 48 scans and 2048× 256 complex points; 1H,13C-HSQCwas
recorded using 256 scans, 1024× 256 complex points and a 13C-
frequency range from 0 to 80 ppm. All spectra were processed
using zero-filling, linear prediction for the indirect dimension of
the DQF-COSY, TOCSY and 1H,13C-HSQC spectra, and squared
cosine apodization in both dimensions. All chemical shifts were
referenced with respect to the on-resonance water signal. Spectra
were processed using NMRPipe (Delaglio et al., 1995). Data
assignment and analysis were performed using the CCPN suite
(Vranken et al., 2005). NOE contacts were converted to distance
restraints with CCPN own routine and dihedral restraints were
inferred using CCPN implementation of DANGLE (Cheung
et al., 2010). The peptides structure models were obtained using
ARIA (Rieping et al., 2007). To calculate structures for Pepcan-
9 at pH 3.0, 76 unambiguous distance restraints and 8 dihedral
restraints were used (60 and 10, respectively, for Pepcan-9 at
pH 7.4). For Pepcan-12 at pH 3.0, 70 unambiguous distance
restraints and 16 dihedral restraints were used (59, and 16,
respectively for Pepcan-12 at pH 7.4). Seven simulated annealing
cycles were performed with 200 structures/step. At the end of
each step the lowest energy structures were used to automatically
improve the peak assignment for the next cycle. On the eighth
iteration, 100 structures were calculated. Of these, the 10 lowest
energy structures were selected and water-refined.
Docking Calculations
The lowest energy structure from the NMR ensembles obtained
for both peptides in NaP/HFIP at pH 7.4 was used for docking
studies. PDB structure 5U09 (Shao et al., 2016) was used
as a model for the CB1 receptor. Docking experiments were
performed with Autodock 4.2 (Morris et al., 2009) with the
Lamarckian Genetic Algorithm (LGA), using Kollman charges
for both the receptor and the peptide. The receptor and the
peptide backbone were kept rigid, the peptide side chains
were allowed to rotate. 100 runs were performed with an
initial population of 500 structures, a maximum number of
2.5 × 106 energy evaluations, and of 2.7 × 105 generations.
Refinement of the lowest energy structure of the Pepcan/CB1
complexes was achieved by in vacuo energy minimization with
the steepest descent in GROMACS 5.1.4 (Pronk et al., 2013),
and the minimized complexes were re-docked with 100 rounds
of local search. Protein-protein docking to define possible
allosteric binding sites for Pepcan-12 was performedwith the web
implementation of FRODOCK (Ramírez-Aportela et al., 2016)
RESULTS AND DISCUSSION
Conformational Analysis by CD
Spectroscopy
The conformation of both peptides in aqueous environment
at acidic and neutral pH, i.e., in 20mM sodium phosphate
buffer (NaP) at pH 3.0 and 7.4, was analyzed by Circular
Dichroism (CD) spectroscopy. The spectra (Figure S1) suggest
that their structure is mostly disordered, as expected for small
size linear peptides in aqueous solution (Pastore and Temussi,
2013). Deconvolution of the spectra indicated a α-helix content of
0 and 6% for Pepcan-9, and 30 and 15% for Pepcan-12 at neutral
and acidic pH, respectively, indicating that the longer peptide
is always more structured than the shorter one, in particular at
neutral pH.
To understand if such conformational preferences are
maintained also in a less polar environment, as would be the case
at the receptor binding site, the conformation of the peptides
was also analyzed in solvent mixtures containing 0 to 100%
hexafluoro-isopropanol (HFIP), at both pH values. It is well-
known that the low polarity of the NaP/HFIP solutions promotes
intra-peptide interactions over peptide-solvent interactions, and
HFIP has been widely used to highlight secondary structure
propensity in hydrophobic environments (Crescenzi et al., 2002;
Tomaselli et al., 2006; Bernardi et al., 2010; Aschi et al., 2017).
As expected, HFIP significantly increases the helical content
in both peptides. The most significant effects were detected for
Pepcan-12 at pH 7.4 (Figure 1), for which even the presence of
as little as 10% of HFIP leads to substantial spectral changes,
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FIGURE 1 | CD spectra of Pepcan-12 in different HFIP/ NaP mixtures, pH 7.4.
The appearance of a signal diagnostic of helical secondary structure is visible
in the presence of as little as 10% HFIP.
FIGURE 2 | Molar ellipticity per residue measured at 222 nm (canonical
minimum of α-helix conformation) as function of HFIP content in the mixture,
for all conditions studied.
pointing to an increase of helical structure (Figure 1, red vs. black
lines). The spectra recorded in the other conditions are reported
in the supplementary material (Figure S2).
Similar but smaller effects were observed for Pepcan-9, where,
upon dissolution in 10% HFIP in NaP, the helical content raised
to 30 %. Monitoring the ellipticity at 222 nm as a marker of the
peptide helicity, the highest helical content was observed between
40 and 70% HFIP, and decreased at higher HFIP concentrations
(Figure 2). Both peptides at both pHs exhibited similar trends
(Figure 2).
NMR Analysis
The two peptides were subjected to NMR characterization in
either aqueous or low polarirty environment, and at both pH
values. Based on the results of the CD analysis, we selected as a
FIGURE 3 | Backbone overlay of the 10 lowest energy NMR-conformations of
Pepcan-9 (A) and Pepcan-12 (B) in 50/50 v/v HFIP/NaP, pH 3.0, and
Pepcan-9 (C) and Pepcan-12 (D) in 50/50 v/v HFIP/NaP, pH 7.4.
suitable low polarity condition the 50/50 NaP/HFIP system, both
peptides appear significantly structured.
A full set of two-dimensional NMR experiments (TOCSY,
NOESY, ROESY, DQF-COSY, and 1H,13C-HSQC) were
employed for proton and carbon resonances assignment. The 1H
and 13C resonances assigned are reported in Tables S1–S8 of the
supplementary material. For structural comparison, the residue
numbering of Pepcan-12 was used in all cases.
In aqueous medium, at both pH values, the spectra exhibit
the typical behavior of intrinsically disordered peptides (Temussi
et al., 1989; Balboni et al., 1990; Pastore and Temussi, 2013),
i.e., poor signal dispersion and no NOE contacts other than
sequential ones (data not shown). Upon dissolution in 50/50
NaP/HFIP, good quality NMR spectra were obtained. Diagnostic
regions of the NOESY and TOCSY spectra for both peptides
at pH 3.0 are reported in Figure S3 of the supplementary
material, together with NOE medium-range contact overviews
bar diagrams obtained under all conditions (Figure S4).
At pH 3.0, diagnostic NN i,i+1 and αN i,i+3 contacts
suggested the presence of helical structure at the C-terminus
of both peptides, with a longer helical segment in Pepcan-12.
Furthermore, the Pro4 was found in the trans conformation.
Based on NOE derived distance restrains and chemical shifts
data, the structures of the two peptides were generated (Figure 3):
a short helical region is present at the C-terminus of Pepcan-
9, between residues 6 and 11 (Figure 3A), whereas Pepcan-12
exhibits a helix spanning from Val5 to Ser11 (Figure 3B).
At pH 7.4, fewer and weaker NOE contacts were observed
for both peptides. For Pepcan-9, diagnostic signals for His12
were no longer observed. Accordingly, the calculated structures
suggest the presence of a helical region in the stretch Asn6-Leu10,
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FIGURE 4 | Superimposition of the structures of (A) Pepcan-9 (orange) and
(B) Pepcan-12 (blue) on the α-chain of hemoglobin (PDB code 2DN1).
while the C-terminal Ser and His are disordered (Figure 3C). In
the case of Pepcan-12, the calculated structure present a helical
region spanning from Asp3 to Ser11 (Figure 3D).
Our NMR data indicate that pH has opposite effects on the
two peptides: for Pepcan-9, a helical structure is favored at acidic
pH, whereas for Pepcan-12 a helical structure is favored at neutral
pH. This finding can be explained on the basis of the protonation
states of His12 (present in both peptides) and Asp3 (present only
in Pepcan-12). At pH 3.0, the side-chain of His12 is protonated,
stabilizing the helical structure at the C-terminus (C-capping).
This can not happen at pH 7.4, where the His12 sidechain is likely
uncharged. In the case of Pepcan-12 this effect is paralleled by the
stabilizing influence of the Asp negative charge at the N-terminal
site (N-capping), which induces a shift of the helix region. Such
further helix stabilization is not possible for Pepcan-9.
HFIP exerts its described helix-stabilizing effect when present
up to 60%, but further decreasing the medium polarity has
detrimental effects on the peptide structure. In fact, the decrease
of the dielectric constant can have a dramatic influence on the
pKa of amino acid side-chains (Spadaccini et al., 2016), due to
the stabilization of uncharged states, which, in this case, would
reduce the positive influence of both helix capping effects.
The structures obtained in our studies closely resemble the
native conformation of the peptides within the α-chain of
hemoglobin (Figure 4) (Park et al., 2006): Cα RMSD between
corresponding residues in the folded stretch of the peptides and
within the protein structure were 0.647 and 0.496 Å for Pepcan-9
and Pepcan-12, respectively, indicating that the 50/50 NaP/HFIP
solvent system can correctly mimic the environment of a protein
interior.
On the other hand, our structures differ substantially from
earlier literature reports employing other systems: previous
studies had elucidated the structure of the rat homolog of Pepcan-
9 in DPC/SDS micelles (Scrima et al., 2010), identifying a regular
type I β-turn at the C-terminus of the peptide and a substantially
disordered N-terminal end. This peptide β-sheet propensity had
also been detected in the presence of 25% trifluoroethanol (TFE),
although no structure could be derived in these conditions
(Bomar et al., 2012).
Docking Studies
In order to understand whether our NMR structures could
correlate to the different bioactivity of Pepcan-9 and 12, we
performed peptide docking on the crystal structure of the CB1
receptor. Pepcan-9 has an antagonist/ inverse agonist effect on
CB1, with a binding affinity and inhibition constant very similar
to those of the synthetic inhibitor rimonabant (Heimann et al.,
2007). The structure of CB1 in complex with the inhibitor
taranabant, a close relative of rimonabant, has recently been
resolved (PDB code 5U09) (Shao et al., 2016), and docking studies
in that framework indicated that taranabant and rimonabant
have similar binding modes, involving a binding pocket located
toward CB1 transmembrane helices TM1 and TM7 (Shao et al.,
2016). We used our lowest energy structure of Pepcan-9 in the
low polarity solvent system and at physiological pH to perform
docking studies on CB1. To preserve the structure based on
NMR restraints, during the docking the peptide backbone was
kept rigid, whereas all side chains were allowed to rotate freely.
Despite the low resolution of this approach, which did not
take into account the flexibility of both binding partners, the
docking results show that the NMR conformation of Pepcan-9
matches the taranabant binding pocket, with a calculated binding
energy of −10.81 kcal/mol (Figure 5). All the residues essential
for taranabant binding are in proximity of the side chains of
Pepcan-9. In particular, Pro4 is in the vicinity of Met103, Phe
174, and Phe177; Phe7 interacts with Phe102, Met103, Ile169,
and Val196 of CB1; Leu9 of Pepcan-9 is in contact with the
side chains of Phe108 and Phe379, Leu10 with Trp279, Leu359,
and Met363. Additionally, a favorable cation-pi interaction can
form between the side chain of Lys8 and Phe170. This extensive
interaction pattern would explain the selectivity that is exhibited
by Pepcan-9 toward CB1 and its high inhibition constant,
meanwhile supporting the fact that the NMR structure in the
50/50 NaP/HFIP solvent system could closely resemble that of
the peptide in its bioactive form.
In the case of Pepcan-12, the same approach could not
be applied, due to the absence of experimental data on the
peptide binding site. Indeed, despite the sequence difference of
only three aminoacids, attempts of docking in the orthosteric
binding pocket produced only complexes with positive binding
energies, due to the occurrence of severe clashes between
Pepcan-12 and CB1, as indicated in Figure S5. Several allosteric
modulators have been identified for CB1, but the location of
their binding site (or sites) on the receptor has yet to be
clarified (Khurana et al., 2017). It should also be noted that
the binding of allosteric modulators is often dependent on the
nature of the orthosteric ligand, further complicating structural
predictions. To date, the best characterized allosteric modulator
of CB1 is the synthetic compound ORG27569. Yet, different
studies have suggested discordant binding pockets: based on
fluorescence labeling studies, a site proximal to the extracellular
membrane and comprising the disulfide bond Cys98-Cys107
has been proposed in combination with the orthosteric ligand
CP55,940 (Fay and Farrens, 2013). Mutagenesis and molecular
modeling studies have also pointed toward a binding site partially
overlapping with that of rimonabant and close to the N-terminus,
involving the interaction with residues K192, F200, W279, and
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FIGURE 5 | Binding of (A) Pepcan-9 (pink) and (B) taranabant (purple) to the CB1 receptor (grey ribbon) (PDB code 5U09). The residues of the receptor in close
proximity to the ligand are displayed as blue sticks.
W356 of the TM helices, as well as with F268 of the EC2
extracellular domain (Shore et al., 2014). This partial overlap of
the orthosteric and allosteric binding sites could explain receptor
modulation through alterations in the dissociation kinetics of
the primary ligand, with variable outcomes depending on the
orthosteric ligand. A different site, in the intracellular portion
of TM1, TM2 and TM4 has instead been proposed on the basis
of computational methods, cross-linking and mass spectrometry
analysis (Stornaiuolo et al., 2015). This site was selected out of
5 potential binding sites unique to CB1, in turn chosen among
9 potential binding sites common to both CB1 and CB2, on a
homology model of CB1. Given the peptide nature of Pepcan-12,
it is plausible that it might employ yet another binding pocket,
compared to synthetic allosteric modulators. Both molecular
dynamics (Shore et al., 2014; Stornaiuolo et al., 2015) and the
comparison of the crystal structures of CB1 bound to diverse
agonists/ antagonists orthosteric ligands (Hua et al., 2016, 2017;
Shao et al., 2016) have suggested a high intrinsicplasticity of
CB1: the crystal structures reveal that the orthosteric binding
site is ∼50% smaller in the case of agonist binding than in
antagonist binding, due to significant movements of TM1 and
TM2 (Hua et al., 2017). This plasticity could be further influenced
by the concomitant binding of allosteric modulators, in ways that
are yet to be completely elucidated. Additionally, peptides are
extremely flexible molecules, and the conformational space of the
ligand should also be explored when performing blind docking
experiments. For all these reasons, the definition of the binding
interactions between Pepcan-12 and CB1 by computational
methods, in the absence of strong experimental data, poses a
considerable challenge. At any rate, to get a hint on whether
the above described NMR structure of Pepcan-12 possessed any
biological significance, we used a simplified approach, trying
to predict its possible binding site by rigid body docking and
shape complementary on the protein surface. Blind docking
experiments on the crystal structure of CB1 revealed only two
likely binding sites: the first (Figure 6, yellow surface), is located
toward the extra-cellular portion, partially overlapped with the
taranabant binding site, whereas the second (Figure 6, green
surface) encompassing a lipid exposed region of TM3, TM4, and
TM5. The first site would be in agreement with previous reports
(Fay and Farrens, 2013, 2015; Shore et al., 2014). Moreover, this
solution seems the most plausible, given the peptidic nature of
the ligand, which would necessitate active ligand transport across
the membrane. Although it is possible that the actual complex
between Pepcan-12 and CB1 will involve yet a different site,
and/or conformational state, and/or some extent of induced fit of
both partners, our NMR structure seems therefore a good starting
point for further structural and computational investigations on
this complex activation mechanism.
DISCUSSION
In an attempt to define the structural determinants of their
bioactivity and aggregation propensity, we have analyzed the
conformational properties of the two most representative
endocannabinoid peptides, Pepcan-9 and Pepcan-12. Pepcan-
12 is an allosteric modulator of both CB1 and CB2 receptors,
and is produced and released in a variety of tissues, also in
response to cellular stress. The existence of Pepcan-9 in vivo has
instead been questioned: experimental data indicate that it could
be a purification artifact from the cleavage of longer peptides.
Nonetheless, many studies have analyzed the effects of exogenous
administration of Pepcan-9, which can also be produced by
synthesis, revealing its interesting pharmacological profile, for
instance in pain and appetite modulation. While in aqueous
environment both peptides are unstructured, the presence of
a low polarity environment increases the content of α-helical
structure and emphasizes conformational differences between
the peptides. In particular, in a 50/50 HFIP/NaP/buffer system,
the structure of both peptides resembles the native conformation
at the N-terminal region of the helix G of hemoglobin. This
validates the idea that such solvent system has potential to
mimic the protein interior. At acidic pH, both peptides present
a helical region at the C-terminus. At neutral pH, the helical
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FIGURE 6 | Possible binding modes of Pepcan-12 (yellow and green
surfaces) to the CB1 receptor (blue ribbon) (PDB code 5U09). The orthosteric
binding site is highlighted by the presence of a taranabant molecule (purple
stick and surface).
region is longer, but slightly shifted toward the N-terminus in
Pepcan-12, whereas it is reduced to a single turn in Pepcan-
9. We have proposed that these latter structures may resemble
the peptide bioactive conformations in vivo. Indeed, by means
of docking studies, we have demonstrated that, in the described
conformation, Pepcan-9 can efficiently bind to CB1, suggesting a
bioactivity similar to that of rimonabant. In the case of Pepcan-
12, the results could not be as detailed as for Pepcan-9, due to
the lack of knowledge on its precise binding pocket on CB1.
Rigid body docking of the Pepcan-12 NMR structure on the
receptor surface led to the detection of two possible binding
sites. The first and most likely is located toward the extracellular
portion of CB1 and partially overlaps with the orthosteric binding
site, in accordance with the results of previous studies on
another CB1 allosteric modulator, ORG27569 (Fay and Farrens,
2013; Shore et al., 2014). The second binding pocket is instead
located in a lipid exposed portion of TM3, TM4 and TM5, but
it seems unlikely a relevant binding location as translocation
mechanisms would be needed for the peptide to reach it. This
docking approach does not allow more detailed predictions of
molecular interactions and additional experimental data are still
needed to clarify the precise binding mode of Pepcan-12 to CB1.
Nevertheless, as one of the putative allosteric binding sites of CB1
was indeed detected, it seems that our results can still provide
the structural basis to design peptide ligands for CB1. It is also
interesting to highlight that, during our experiments, including a
period of several days needed for NMR experiment acquisition,
no aggregation nor precipitation was observed for either peptide
in any condition explored. This is in apparent contrast with
previous literature reports on formation of fibrils by Pepcan-
9 (Bomar et al., 2012). In those reports, the conformational
properties of Pepcan-9 were studied upon the addition of
25% TFE, a condition known to promote secondary structure,
which led to the observation of β-like structure. Similarly, a
β-turn characterized the structure of Pepcan-9 in DPC/SDS
micelles. Possibly, the helical and β-strand forms of Pepcan-9
are coexistent, and the preference toward either conformation
could direct the aggregation behavior of Pepcan-9, interfering
with its CB1 activity. We hypothesize that peptide modifications
aimed to stabilize the described helical conformation and avoid
β-strand formation and aggregation might be a first step in the
development of selective peptide-based CB1 ligands.
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